George Clinical Rebrands as Emerald Clinical Trials

April 07, 2025 10:00 AM AEST | By Cision

George Clinical Rebrands as Emerald Clinical Trials — Image source: Kalkine Media

Recent News

JPMorgan CEO Jamie Dimon discusses cautious clients and recession risk

Booz Allen, Accenture stocks fall on Pentagon contract cancellations

Morgan Stanley downgrades Joby on volatile macro outlook and tariff ri...

Three Pioneers’ Trailblazing Food Recovery Work

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials

SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased to announce it has rebranded to become Emerald Clinical Trials. This strategic name change underscores the company's well-established position as a dedicated, reliable, consistent, and flexible CRO, while mitigating global clinical development risks through deep therapeutic and local expertise cultivated over 20 years.

Emerald Clinical Trials continues to focus on end-to-end services across all therapeutic areas designed to change lives⁠ while ⁠advancing innovations that help evolve global clinical research practices. With its strong track record in Oncology and Cardio-Renal-Metabolic (CRM) therapeutic areas, trusted expertise in Asia Pacific, and global scientific leadership, Emerald Clinical Trials is a highly differentiated clinical CRO on the world stage. The company's extensive reach – operating directly in 42 countries and in 70 countries through partnerships – ensures seamless execution of clinical trials worldwide.

The new brand amplifies the exceptional work of Emerald Clinical Trials and highlights the breadth and depth of its experience to an even broader audience. It emphasizes a strong commitment to patients, customers, and partners.

The company's deep commitment to customer-centricity fosters long-term relationships built on trust, reliability, and measurable success. Emerald's ability to deliver predictability in clinical trials is underscored by a track record of repeat business, industry excellence awards, and consistent performance in bringing therapies to market.

"For the past two decades, Emerald Clinical Trials has been focused on delivering high quality trials that combine a global reach with a high-touch approach. We offer the footprint and expertise of a large CRO with the personalized attention and flexibility of a smaller partner, ensuring that every client, from emerging biotech to top-tier pharma, receives the focused, hands-on support they need to de-risk their clinical programs," said Mary Gunn, CEO, Emerald Clinical Trials. "This exciting transformation strengthens our position as a trusted partner in clinical trials, while reaffirming our commitment to our clients and core values."

"We decided early on that we wanted to work with a CRO that has a flexible approach, and solutions tailored to the specific needs of each trial, whether accelerating timelines, adapting to evolving study requirements, or scaling resources efficiently," said Dr. Daniel Tillett, CEO, Race Oncology, an Emerald client. "Agility is critical for biopharma companies that require a partner who can pivot alongside them, rather than slow them down with bureaucratic inefficiencies, and that is truly a strength of Emerald Clinical Trials."

About Emerald Clinical Trials
Emerald Clinical Trials is a leading clinical research organization operating worldwide that serves over 100 biotechs, and 6 of the top 10 pharmaceutical companies. Headquartered in Singapore and driven by operational expertise and scientific excellence, the company provides comprehensive clinical trial services to clients globally, offering solutions across all trial phases. For more information, visit www.emeraldclinical.com.

Media Contact: Shannon Severino, [email protected], T +1 412 608 2393

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.